natgillin/translations-raw huggingface dataset:
SVR12-raterne var statistisk signifikant højere for patienter, der fik simeprevir sammen med peginterferon alfa-2a eller peginterferon alfa-2b og ribavirin (henholdsvis 88% og 78%), sammenlignet med patienter, der fik placebo sammen med peginterferon alfa-2a eller peginterferon alfa-2b og ribavirin (henholdsvis 62% og 42%) (studie C216). 
SVR12 rates were statistically significantly higher for patients receiving simeprevir with peginterferon alfa-2a or peginterferon alfa-2b and ribavirin (88% and 78%, respectively) compared to patients receiving placebo with peginterferon alfa-2a or peginterferon alfa-2b and ribavirin (62% and 42%, respectively) (study C216).
Tabel 11: Studier udført med simeprevir + sofosbuvir: population og resumé af studiedesign Antal inkluderede patienter 
Table 11: Studies conducted with simeprevir + sofosbuvir: population and summary of study design
I en biokemisk analyse hæmmede simeprevir den proteolytiske aktivitet af rekombinant genotype 1a og 1b HCV NS3/4A-proteaser med mediane Ki -værdier på henholdsvis 0,5 nM og 
In a biochemical assay, simeprevir inhibited the proteolytic activity of recombinant genotype 1a and 1b HCV NS3/4A proteases, with median Ki values of 0.5 nM and 1.4 nM, respectively.
Tag derefter den næste dosis OLYSIO på det sædvanlige tidspunkt. 
Then continue taking OLYSIO at the usual scheduled time.
Der opstod udslæt eller kløe grad 3 hos henholdsvis 0,5% og 0,1% af de simeprevir-behandlede patienter. 
Grade 3 rash or pruritus occurred in 0.5% and 0.1% of simeprevir-treated patients, respectively.
Tabel 14 viser responsraterne for patienter uden cirrose (METAVIR-score F0-3), der fik 12 ugers behandling med simeprevir + sofosbuvir med eller uden ribavirin; forlængelse af behandlingen til 24 uger øgede ikke responsraterne sammenlignet med 12 ugers behandling. 
Table 14 shows the response rates for patients without cirrhosis (METAVIR scores F0-3) receiving 12 weeks of simeprevir +sofosbuvir with or without ribavirin; extending treatment to 24 weeks did not increase response rates in comparison with 12 weeks treatment.
Genotype 1a- og 1b-isolater med en Q80Kpolymorfisme ved baseline medførte en median FC for simeprevir-EC50 på henholdsvis 11 (N = 33) og 8,4 (N = 2). 
Genotype 1a and 1b isolates with a baseline Q80K polymorphism resulted in median FC in simeprevir EC50 of 11 (N = 33) and 8.4 (N = 2), respectively.
- Hvis du er mand, må din kvindelige partner ikke blive gravid, så længe du er i behandling og i flere måneder efter, behandlingen er stoppet. 
- If you are a man, your female partner must not become pregnant during your treatment and
Simeprevir elimineres gennem biliær udskillelse. 
Elimination of simeprevir occurs via biliary excretion.
Forhøjet bilirubin i blodet af grad 2 blev indberettet for en enkelt patient (0,3%), der fik 12 ugers behandling. 
Grade 2 ‘blood bilirubin increased' was reported in one patient (0.3%) receiving 12 weeks of treatment.
De farmakokinetiske parametre for simeprevir var sammenlignelige hos patienter med HCVgenotype 1-infektion med og uden samtidig HIV-1-infektion. 
Pharmacokinetic parameters of simeprevir were comparable between patients with HCV genotype 1 infection with or without HIV-1 co-infection.
Behandlingsuge 12: ≥ 25 IE/ml 
Treatment week 12: ≥ 25 IU/ml
Under administration af simeprevir sammen med peginterferon alfa og ribavirin var stigningerne i direkte og indirekte bilirubin generelt ikke forbundet med stigninger i leveraminotransferaser og blev normaliseret efter afslutning af behandlingen. 
During administration of simeprevir with peginterferon alfa and ribavirin, the elevations in direct and indirect bilirubin were generally not associated with elevations in liver transaminases and normalised
Plasmakoncentrationen af midazolam blev ikke påvirket efter intravenøs administration, da simeprevir ikke hæmmer CYP3A4 i leveren. 
Plasma concentrations of midazolam were not affected when administered intravenously as simeprevir does not inhibit hepatic CYP3A4.
Læs indlægssedlerne til disse lægemidler med information om doseringen af dem samt instruktioner til anvendelsen. 
Read the package leaflets for these medicines for their dosage and directions on ‘how to take' them.
Moderate og potente CYP3A4hæmmere øger plasmaeksponeringen af simeprevir markant, og moderate og potente CYP3A4induktorer reducerer plasmaeksponeringen af simeprevir markant. 
Moderate or strong inhibitors of CYP3A4 significantly increase the plasma exposure of simeprevir, and moderate or strong inducers of CYP3A4 significantly reduce plasma exposure of simeprevir.
Behandlingsuge 4: ≥ 25 IE/ml 
Treatment week 4: ≥ 25 IU/ml
Kapslen skal sluges hel. 
The capsule should be
Kvindelige patienter i den fertile alder skal anvende sikker kontraception (se pkt. 
Female patients of childbearing potential must use an effective form of contraception (see section 4.6).
Indehaveren af markedsføringstilladelsen skal inden for den fastsatte tidsramme gennemføre følgende 
The MAH shall complete, within the stated timeframe, the below measures:
Hos patienter med HCV-genotype 1a opstod R155K hovedsagelig alene eller i kombination med aminosyresubstitutioner ved NS3-positionerne 80, 122 og/eller 168, mens patienter med HCV-genotype 1b oftest havde en opstået D168V-substitution (tabel 10). 
Patients with HCV genotype 1a predominantly had emerging R155K alone or in combination with amino acid substitutions at NS3 positions 80, 122 and/or 168, while patients with HCV genotype 1b had most often an emerging D168V substitution (table 10).
Simeprevir hæmmer optagelsestransportørerne OATP1B1/3 og NTCP samt effluxtransportørerne P-gp/MDR1, MRP2, BCRP og BSEP. 
Simeprevir inhibits the uptake transporters OATP1B1/3 and NTCP and the efflux transporters P-gp/MDR1, MRP2, BCRP and BSEP.
Der henvises til produktresumeerne for peginterferon alfa og ribavirin for information om krav til laboratorietest før, under og efter behandlingen, herunder krav til hæmatologiske og biokemiske test (inklusive leverenzymer og bilirubin) samt graviditetstest. 
Refer to the Summary of Product Characteristics of peginterferon alfa and ribavirin for pre-treatment, on-treatment and post-treatment laboratory testing requirements including haematology, biochemistry (including hepatic enzymes and bilirubin), and pregnancy testing requirements.
Data fra et 3-årigt opfølgningsstudie med patienter, der ikke opnåede SVR med simeprevir i kombination med peginterferon alfa og ribavirin i et tidligere fase 2- eller fase 3-studie, viste, at hos 86% (37/43) af disse patienter kunne de opståede mutationer på tidspunktet for svigt i det tidligere studie ikke længere påvises efter en median opfølgningtid på 180 uger (intervallet 47-230 uger) (studie 
Data from a 3-year follow-up study in patients who did not achieve SVR with simeprevir in combination with peginterferon alfa and ribavirin in a previous phase 2 or phase 3 study showed that in 86% (37/43) of these patients the emerging mutations at time of failure in the previous study were no longer detected after a median follow-up of 180 weeks (range 47-230 weeks) (study HPC3002).
Henholdsvis 71% (37/52), 93% (14/15), 80% (8/10) og 36% (10/28) af de simeprevir-behandlede, behandlingsnaive patienter, patienter med tidligere recidiv, tidligere delvist respons og tidligere nul respons havde udetekterbart HCV-RNA ved uge 4. 
Seventy-one percent (37/52), 93% (14/15), 80% (8/10) and 36% (10/28) of simeprevir-treated treatment-naïve patients, prior relapsers, prior partial responders and prior null responders had undetectable HCV RNA at week 4.
Bivirkninger af grad 3 eller 4 blev indberettet for 3,1% af de patienter, der fik simeprevir sammen med peginterferon alfa og ribavirin, versus 0,5% af de patienter, der fik placebo sammen med peginterferon alfa og ribavirin. 
Grade 3 or 4 adverse reactions were reported in 3.1% of patients receiving simeprevir with peginterferon alfa and ribavirin versus 0.5% of patients receiving placebo with peginterferon alfa and ribavirin.
De opståede NS3-aminosyresubstitutioner svarede til dem, der observeres hos patienter, som ikke opnåede SVR efter behandling med simeprevir i kombination med peginterferon alfa og ribavirin. 
The emerging NS3 amino acid substitutions were similar to those observed in patients who did not achieve SVR following treatment with simeprevir in combination with peginterferon alfa and ribavirin.
udslæt*, kløe* 
rash*, pruritus*
Det anbefales ikke at administrere OLYSIO sammen med systemisk fluconazol eller voriconazol. 
It is not recommended to co-administer OLYSIO with systemic fluconazole or voriconazole.
kvalme obstipation almindelig forhøjet blodbilirubin* forhøjet blodbilirubin* forhøjet blodbilirubin* 
Gastrointestinal disorders: very common nausea constipation common blood bilirubin increased* blood bilirubin increased* blood bilirubin increased* Skin and subcutaneous tissue disorders:
Dosisjustering på baggrund af legemsvægt eller BMI er ikke nødvendig. 
No dose adjustment is necessary based on body weight or body mass index.
Tabel 9: Antiviral aktivitet af monoterapi med simeprevir 200 mg (studie C201 og C202) Gennemsnitlig (SE) ændring i HCV-RNA på dag 7/8 (log10 IE/ml) 
Table 9: Antiviral activity of simeprevir 200 mg monotherapy (studies C201 and C202) Mean (SE) change in HCV RNA at day 7/8 (log10 IU/mL)
OLYSIO i kombination med peginterferon alfa og ribavirin: Hos HCV/HIV-1-coinficerede patienter er behandlingsvarigheden den samme som for HCV-monoinficerede patienter; dog skal coinficerede patienter med cirrose have 36 ugers behandling med peginterferon alfa og ribavirin efter at have fuldført 12 ugers behandling med OLYSIO, peginterferon alfa og ribavirin (total behandlingsvarighed 
OLYSIO in combination with peginterferon alfa and ribavirin: HCV/HIV-1 co-infected patients should be treated for the same duration as HCV mono-infected patients, except for co-infected patients with cirrhosis who should receive 36 weeks of treatment with peginterferon alfa and ribavirin after completing 12 weeks of treatment with OLYSIO, peginterferon alfa and ribavirin (total treatment
Kimære replikoner, der bærer NS3sekvenser fra HCV-PI-behandlingsnaive patienter med genotype 1a og genotype 1b, viste en median fold-ændring (FC) i simeprevirs EC50-værdier på henholdsvis 1,4 (N = 78) og 0,4 (N = 59) sammenlignet med reference-genotype 1b-replikonet. 
Chimeric replicons carrying NS3 sequences derived from HCV PI treatment-naïve genotype 1a and genotype 1b patients displayed median fold change (FC) in simeprevir EC50 values of 1.4 (N = 78) and 0.4 (N = 59) compared to reference genotype 1b replicon, respectively.
Bivirkninger af simeprevir i kombination med sofosbuvir eller i kombination med peginterferon alfa og ribavirin, der er indberettet for voksne patienter med HCV-genotype 1-infektion, vises i tabel 5. 
Adverse reactions of simeprevir in combination with sofosbuvir or in combination with peginterferon alfa and ribavirin reported in adult patients with HCV genotype 1 infection are listed in table 5.
til Modification of Diet in Renal Disease [MDRD] eGFR-formlen; eGFR ≥ 80 ml/min) var det gennemsnitlige AUC for simeprevir ved steady state 1,62 gange højere (90% konfidensinterval: 0,73-3,6) hos personer med svær nyreinsufficiens (eGFR under 30 ml/min). 
Compared to healthy subjects with normal renal function (classified using the Modification of Diet in Renal Disease [MDRD] eGFR formula; eGFR ≥ 80 ml/min), the mean steady-state AUC of simeprevir was 1.62-fold higher (90% confidence interval: 0.73-3.6) in subjects with severe renal impairment (eGFR below 30 ml/min).
Det anbefales ikke at administrere OLYSIO sammen med darunavir/ritonavir. 
It is not recommended to co-administer OLYSIO with darunavir/ritonavir.
OLYSIO i kombination med peginterferon alfa og ribavirin Det er usandsynligt, at patienter med utilstrækkeligt virologisk respons under behandlingen vil opnå et vedvarende virologisk respons (SVR). 
OLYSIO in combination with peginterferon alfa and ribavrin It is unlikely that patients with inadequate on-treatment virologic response will achieve a sustained virologic response (SVR), therefore discontinuation of treatment is recommended in these patients.
Der er efter markedsføring indberettet leverdekompensation og leverinsufficiens, herunder fatale tilfælde, hos patienter, der blev behandlet med OLYSIO i kombination med peginterferon alfa og ribavirin og i kombination med sofosbuvir. 
Hepatic decompensation and hepatic failure, including fatal cases, have been reported post-marketing in patients treated with OLYSIO in combination with peginterferon alfa and ribavirin and in combination with sofosbuvir.
Læs indlægssedlerne til de andre lægemidler for information om at køre motorkøretøj og 
Read the package leaflets for these other medicines for information regarding driving and using machines.
Samtidig administration af OLYSIO og stoffer, der i moderat eller kraftig grad inducerer eller hæmmer cytokrom P450 3 A (CYP3A4), anbefales ikke, da dette i signifikant grad kan henholdsvis reducere eller øge eksponeringen af simeprevir. 
Co-administration of OLYSIO with substances that moderately or strongly induce or inhibit cytochrome P450 3A (CYP3A4) is not recommended as this may lead to significantly lower or higher
Stigningerne i amylase og lipase var ikke forbundet med pancreatitis. 
Amylase and lipase elevations were not
Test for NS3 Q80K-polymorfisme hos patienter inficeret med HCV-genotype 1a inden behandling 
Pre-treatment testing for NS3 Q80K polymorphism in patients infected with HCV genotype 1a
Det anbefales ikke at administrere OLYSIO sammen med nogen HIVPI'er med eller uden ritonavir. 
It is not recommended to co-administer OLYSIO with any HIV PI, with or without ritonavir.
Simeprevir metaboliseres fortrinsvis i leveren. 
Simeprevir is primarily metabolised by the liver.
For patienter, der har høj risiko for leverdekompensation eller leverinsufficiens, skal leverfunktionstestene derfor monitoreres inden og (efter klinisk behov) under kombinationsbehandling med OLYSIO. 
Therefore, in patients who are at high risk for hepatic decompensation or hepatic failure, liver function tests should be monitored before and as clinically indicated during OLYSIO combination therapy.
OLYSIO skal bruges i kombination med andre lægemidler til behandling af CHC (se pkt. 
OLYSIO must be used in combination with other medicinal products for the treatment of CHC (see section 5.1).
Der blev observeret mønstre, som er specifikke for HCV-genotype 1-undertyper af aminoresyresubstitutioner opstået i forbindelse med behandling med simeprevir, hos patienter, der ikke opnåede SVR. 
HCV genotype 1 subtype-specific patterns of simeprevir treatment-emergent amino acid substitutions were observed in patients not achieving SVR.
Populationsfarmakokinetiske estimater for eksponeringen af simeprevir var sammenlignelige mellem kaukasiske og sorte/afroamerikanske HCV-inficerede patienter, der blev behandlet med simeprevir i kombination med peginterferon alfa og ribavirin. 
Population pharmacokinetic estimates of exposure of simeprevir were comparable between Caucasian and Black/African American HCV infected patients treated with simeprevir in combination with peginterferon alfa and ribavirin.
Den samlede SVR12-rate for patienter uden cirrose, der fik 8 ugers behandling med simeprevir + sofosbuvir, var 83% (128/155); alle patienter, der ikke opnåede SVR12, havde virusrecidiv (17%; 27/155). 
The overall SVR12 rate for patients without cirrhosis receiving 8 weeks of simeprevir + sofosbuvir was 83% (128/155); all patients not achieving SVR12 had viral relapse (17%; 27/155).
Vedvarende virologisk respons (SVR) var det primære endemål i alle studier og blev defineret som detekterbart eller ikke-detekterbart HCV-RNA < nedre kvantificeringsgrænse (LLOQ) 12 uger (SVR12) eller 24 uger (SVR24) efter den planlagte behandlingsafslutning (studierne C206, C208, C212, C216, HPC2002, HPC3007 og HPC3011) eller efter den faktiske behandlingsafslutning (studierne HPC2014, HPC3017, HPC3018 og HPC3021) (LLOQ på 25 IE/ml og en detektionsgrænse på 15 IE/ml, bortset fra studierne HPC2014 og HPC3021, hvor LLOQ og detektionsgrænsen var 
Sustained virologic response (SVR) was the primary endpoint in all studies and was defined as HCV RNA less than the lower limit of quantification (LLOQ) detectable or undetectable 12 weeks (SVR12) or 24 weeks (SVR24) after the planned end of treatment (studies C206, C208, C212, C216, HPC2002, HPC3007 and HPC3011) or after the actual end of treatment (studies HPC2014, HPC3017, HPC3018 and HPC3021) (LLOQ of 25 IU/ml and limit of detection of 15 IU/ml, except in studies HPC2014 and HPC3021 where LLOQ and limit of detection were 15 IU/ml).
Det anbefales ikke at administrere OLYSIO sammen med astemizol og terfenadin. 
It is not recommended to co-administer OLYSIO with astemizole or terfenadine.
Hjælpestof i OLYSIO-kapslerne 
Excipient of OLYSIO capsules
Fortæl det også til din læge, hvis du tager lægemidler til behandling af en uregelmæssig hjerterytme 
In addition, tell your doctor if you take any medicines used to treat irregular heart beat or high blood
Bivirkninger af grad 2 og 3 blev indberettet for henholdsvis 3,5% (n = 10) og 0,3% (n = 1) af patienterne, der fik 12 ugers behandling med simeprevir sammen med sofosbuvir. 
Grade 2 and 3 adverse reactions were reported in 3.5% (n = 10) and 0.3% (n = 1) of patients, respectively, receiving 12 weeks simeprevir with sofosbuvir; no grade 4 adverse reactions were reported.
Patienter med cirrose N = 103 % (n/N) 
Patients with cirrhosis N = 103 % (n/N)
I den puljede analyse af patienter, der fik 150 mg simeprevir i kombination med peginterferon alfa og ribavirin i de kontrollerede fase 2- og fase 3-studier, var behandlingsrelaterede varianter af simeprevir-resistens ikke længere detekterbarte hos 90 ud af 180 patienter (50%), da studierne var afsluttet efter en median opfølgningtid på 28 uger (intervallet 0-70 uger). 
In the pooled analysis of patients receiving 150 mg simeprevir in combination with peginterferon alfa and ribavirin in the controlled phase 2 and phase 3 studies, treatment-emergent simeprevir-resistance variants were no longer detectable in 90 out of 180 patients (50%) at the end of the studies after a median follow-up of 28 weeks (range 0-70 weeks).
Simeprevir er kraftigt proteinbundet, og det er derfor usandsynligt, at dialyse vil medføre signifikant fjernelse af simeprevir (se pkt. 
Simeprevir is highly protein bound, therefore dialysis is unlikely to result in significant removal of
De 167 inkluderede patienter havde en medianalder på 57 år (27 til 70 år, heraf 5% over 65 år); 64% var mænd; 81% var hvide, 19% var sorte eller afroamerikanske, og 21% var latinamerikanske; 37% havde BMI ≥ 30 kg/m2; median HCV-RNA ved baseline var 
The 167 enrolled patients had a median age of 57 years (range 27 to 70 years; with 5% above 65 years); 64% were male; 81% were White, 19% Black or African American, and 21% Hispanic; 37% had a BMI ≥ 30 kg/m2; the median baseline HCV RNA level was 6.7 log10 IU/ml;
Da eksponeringen for lægemidlet kan være forhøjet hos HCV-inficerede patienter med svær nyreinsufficiens, anbefales forsigtighed ved ordination af simeprevir til disse patienter (se pkt. 
As exposure may be increased in HCV infected patients with severe renal impairment, caution is recommended when prescribing simeprevir to these patients (see section 4.2).
Samtidig administration af OLYSIO og moderate eller potente CYP3A4-hæmmere kan øge plasmaeksponeringen af simeprevir markant, mens samtidig administration af moderate eller potente CYP3A4-induktorer kan reducere plasmaeksponeringen af simeprevir markant og føre til manglende effekt (se tabel 4). 
Co-administration of OLYSIO with moderate or strong inhibitors of CYP3A4 may significantly increase the plasma exposure of simeprevir, while co-administration with moderate or strong inducers of CYP3A4 may significantly reduce the plasma exposure of simeprevir and lead to loss of efficacy (see table 4).
Efter tidligere behandling med interferon (pegyleret eller ikke-pegyleret) med eller uden ribavirin (se pkt. 
Following prior treatment with interferon (pegylated or non-pegylated), with or without ribavirin (see section 5.1).
96% af simeprevir-udvalgte genotype 1-replikoner bar en eller flere aminosyresubstitutioner ved NS3protease-positionerne 43, 80, 155, 156 og/eller 168, hvor substitutioner ved NS3-position D168 var hyppigst observeret (78%). 
Ninety-six percent of simeprevir-selected genotype 1 replicons carried one or multiple amino acid substitutions at NS3 protease positions 43, 80, 155, 156, and/or 168, with substitutions at NS3 position D168 being most frequently observed (78%).
I studie HPC3011 med HCV-genotype 4-inficerede patienter havde 28 ud af 32 (88%) patienter, der ikke opnåede SVR, opståede aminosyresubstitutioner ved NS3-positionerne 80, 122, 155, 156 og/eller 168 (fortrinsvis substitution ved position 168: 24 ud af 32 [75%] patienter), svarende til de opståede aminosyresubstitutioner, der er observeret i patienter, som er inficerede med genotype 1. 
In study HPC3011 in HCV genotype 4 infected patients, 28 of 32 (88%) patients who did not achieve SVR had emerging amino acid substitutions at NS3 positions 80, 122, 155, 156 and/or 168 (mainly substitutions at position 168; 24 out of 32 [75%] patients), similar to the emerging amino acid substitutions observed in genotype 1 infected patients.
I studie HPC3007 var 93% (241/260) af de simeprevir-behandlede patienter egnede til en samlet behandlingsvarighed på 24 uger; SVR12-raten var 83% hos disse patienter. 
In study HPC3007, 93% (241/260) of the simeprevir-treated patients were eligible for a total treatment duration of 24 weeks; in these patients the SVR12 rate was 83%.
og AUC for simeprevir var sammenlignelige ved administration af simeprevir sammen med peginterferon alfa og ribavirin og ved administration af simeprevir alene. 
Plasma Cmax and AUC of simeprevir were similar during co-administration of simeprevir with peginterferon alfa and ribavirin compared with administration of simeprevir alone.
Plasmaeksponeringen af simeprevir (AUC) hos HCVinficerede patienter var cirka 2-3 gange højere end den, der blev observeret hos de raske deltagere. 
Plasma exposure of simeprevir (AUC) in HCV infected patients was about 2- to 3-fold higher compared to that observed in healthy subjects.
24 ugers OLYSIO + sofosbuvir eller 12 ugers OLYSIO + sofosbuvir + ribavirin 
24 weeks OLYSIO + sofosbuvir or 12 weeks OLYSIO + sofosbuvir + ribavirin
OLYSIO 150 mg kapsler simeprevir 
OLYSIO 150 mg capsules simeprevir
Der henvises til produktresumeerne for disse samtidigt administrerede lægemidler for information om deres potentielle virkning på evnen til at føre motorkøretøj og betjene maskiner. 
Refer to the Summary of Product Characteristics for these co-administered medicinal products regarding their potential effect on the ability to drive and use
Interaktionen mellem simeprevir og lægemidlet blev undersøgt i et farmakokinetisk fase 2-studie med 20 HCV-inficerede patienter. 
The interaction between simeprevir and the medicinal product was evaluated in a phase 2 pharmacokinetic study in 20 HCV-infected patients.
Betydningen af tidligere simeprevireksponering hos patienter, der ikke opnår SVR, for effekten af senere HCV NS3/4A-PI-baserede behandlingsregimer er ikke klarlagt. 
The impact of prior exposure to simeprevir in patients not achieving SVR on the efficacy of subsequent HCV NS3/4A PI-based treatment regimens has not been established.
De fleste lysfølsomhedsreaktioner hos simeprevir-behandlede patienter var af let eller moderat sværhedsgrad (grad 1 eller grad 2); 0,3% af de simeprevir-behandlede patienter havde alvorlige reaktioner førende til 
Most photosensitivity reactions in simeprevir-treated patients were of mild or moderate severity (grade 1 or 2); 0.3% of the simeprevir-treated patients experienced serious reactions leading to hospitalisation (see section 4.4).